Molina Healthcare: Slashed Earnings Outlook, Exchange Contraction, and Policy Uncertainty Drive Underperform (Sell) Rating

Bank of America Securities analyst Kevin Fischbeck reiterated a Sell rating on Molina Healthcare today and set a price target of $145.00.

Kevin Fischbeck has given his Sell rating due to a combination of factors tied to Molina Healthcare’s sharply reduced earnings outlook and heightened uncertainty in key businesses. He highlights that the company’s 2026 EPS guidance of $5 is dramatically lower than its prior indication of about $14, reflecting weaker-than-expected Medicaid margins, significant implementation costs for the new Florida Medicaid contract, and ongoing losses in its Medicare Advantage Prescription Drug (MAPD) plans, which Molina now plans to exit in 2027. While the revised Medicaid medical loss ratio (MLR) assumptions now more closely resemble those of major peers, he notes that the company’s expectation of a 510-basis-point improvement in exchange MLR is difficult to underwrite given limited clarity on how the risk pool will change once enhanced premium subsidies expire.

At the same time, Molina is projecting a steep 66% reduction in exchange membership—much larger than anticipated declines for the overall marketplace—which underscores its strategy of prioritizing margins but also introduces volume risk. Although management estimates that its “new store” embedded earnings power has improved, Fischbeck cautions that any benefit could take longer to materialize if industry-wide margins remain compressed. He therefore lowers his earnings estimates and reduces his price objective to $145, assigning a higher multiple on more conservative 2027 EPS forecasts but still seeing downside from the current share price. Overall, he reiterates an Underperform (Sell) rating due to low visibility into the company’s ability to achieve its ambitious margin improvements across Medicaid and exchanges amid significant business mix changes and policy-related uncertainties.

In another report released today, Barclays also maintained a Sell rating on the stock with a $164.00 price target.